Important information from Bayer AG:

This is neither an offer to purchase nor a solicitation of an offer to sell
shares or American depositary shares of Schering AG. The offer has been
made by Dritte BV GmbH, a wholly-owned subsidiary of Bayer AG, for all
bearer shares with no par value of Schering AG (including all bearer shares
with no par value represented by American depository shares). The terms and
conditions of the offer, including any possible extension of the acceptance
period in case of a competing offer by a third party, have been published
in the offer document after the permission of the German Federal Financial
Supervisory Authority (Bundesanstalt fur Finanzdienstleistungsaufsicht,
BaFin) has been obtained on April 12, 2006. Dritte BV GmbH also has filed a
tender offer statement with the U.S. Securities Exchange Commission (SEC)
with respect to the takeover offer. Investors and holders of shares and
American depositary shares of Schering AG are strongly advised to read the
tender offer statement and other relevant documents regarding the takeover
offer filed by Dritte BV GmbH with the SEC because they contain important
information. Investors and holders of shares and American depositary shares
of Schering AG will be able to receive these documents free of charge at
the SEC's web site (http://www.sec.gov), or at the web site
http://www.bayer.com.

This is not an offer of Bayer AG's securities for sale in the United
States. No such securities have been registered under the U.S. Securities
Act of 1933, as amended, and no such securities may be offered or sold in
the United States absent registration or an exemption from registration.
Any public offering of securities to be made in the United States must be
made by means of a prospectus that contains detailed information about the
issuer, its management and its financial statements.

Bayer AG has been granted exemptive relief from the provisions of Rule 14e-
5 under the U.S. Securities Exchange Act of 1934, as amended, permitting it
(or Dritte BV GmbH or certain of its other affiliates or financial
institutions on its behalf) to make purchases of shares of Schering AG
outside of the takeover offer until the end of the offer period, subject to
certain conditions. Accordingly, to the extent permissible under applicable
securities laws and in accordance with normal German market practice, Bayer
AG, Dritte BV GmbH or its nominees or its brokers (acting as agents) may
from time to time make certain purchases of, or arrangements to purchase,
shares of Schering AG outside the United States, other than pursuant to the
offer, before or during the period in which the offer is open for
acceptance. These purchases may occur either in the open market at
prevailing prices or in private transactions at negotiated prices. Any
information about such purchases will be disclosed as required by
applicable securities laws.

The distribution of this announcement and the offer and sale of the
securities described in this announcement in certain jurisdictions may be
restricted by law. Any persons reading this announcement should inform
themselves of and observe any such restrictions. This announcement may not
be taken, distributed or transmitted, directly or indirectly, in any form
in or into Italy or Canada.

This communication is directed only at persons who (i) are outside Italy,
the United Kingdom, Canada or Japan or (ii) have professional experience in
matters relating to investments or (iii) are persons falling within Article
49 (2)(a) to (d) ("high net worth companies, unincorporated associations
etc") of The Financial Services and Markets Act 2000 (Financial Promotion)
Order 2001 (all such persons together being referred to as "relevant
persons"). This communication must not be acted on or relied on by persons
who are not relevant persons. Any investment or investment activity to
which this communication relates is available only to relevant persons and
will be engaged in only with relevant persons.

This announcement is not an offer of securities for sale in Germany and is
not a listing prospectus according to the German Securities Prospectus Act
(Wertpapierprospektgesetz) as amended, the Commission Regulation (EC) No
809/2004 of 29 April 2004 as amended, or any other laws applicable in
Germany governing the issue, offering and sale of securities. Any
investment decisions or advices for investment decisions should only be
made or given based on a prospectus which also includes a section on risk
factors.

Important information from Schering AG:

Schering Aktiengesellschaft has filed a solicitation/recommendation
statement with the U.S. Securities and Exchange Commission relating to the
tender offer for the ordinary shares and American depositary shares of
Schering Aktiengesellschaft by Dritte BV GmbH, a wholly owned subsidiary of
Bayer Aktiengesellschaft. Holders of ordinary shares and American
depositary shares of Schering Aktiengesellschaft are advised to read such
solicitation/recommendation statement because it contains important
information. Holders of ordinary shares and American depositary shares of
Schering Aktiengesellschaft may obtain such solicitation/recommendation
statement, and other filed documents, free of charge at the U.S. Securities
and Exchange Commission's website (http://www.sec.gov) and at Schering
Aktiengesellschaft's website (http://www.schering.de).

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In order to utilize the "Safe Harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995, Schering
Aktiengesellschaft (the "Company") is providing the following cautionary
statement. Except for historical information, statements contained in this
Current Report on Form 6-K may constitute forward-looking statements. The
words "believe", "anticipate", "expect", "intend", "estimate", "plan",
"assume", "will", "may", "should", "risk" and other similar expressions are
predictions of or indicate future events and future trends which do not
relate to historical matters but identify forward-looking statements. In
addition, this annual report includes forward-looking statements relating
to our potential exposure to various types of market risks, such as foreign
exchange rate risk, interest rate and other risks related to financial
assets and liabilities and equity price risk. You should not rely on
forward-looking statements because they involve known and unknown risks,
uncertainties and other factors which are, in many cases, beyond our
control and may cause our actual results, performance or achievements to
differ materially from anticipated future results, performance or
achievements expressed or implied by the forward-looking statements and
from past results, performance or achievements. Certain factors that may
cause such differences include but are not limited to the following:

- - governmental factors, including legislative and regulatory changes;

- - difficulties and uncertainties related to new product development;

- - delays and uncertainties in the product approval process;

- - factors affecting our ability to obtain or maintain patent or
  trademark protection for our key products and processes;

- - factors adversely affecting the sale of our key products, including
  safety or efficacy concerns, increased competition from other
  products or manufacturing or supply disruptions;

- - competitive factors, including pricing and product initiatives of our
  competitors;

- - legal factors, including product liability or other liability claims;

- - factors relating to the implementation of strategic, operational and
  organizational initiatives;

- - human resources factors, including our ability to attract and retain
  qualified personnel;

- - economic factors over which we have no control, including changes in
  inflation, interest rates and foreign currency exchange rates, and
  overall economic conditions particularly in areas such as Asia,
  Eastern Europe and Latin America;

- - adverse developments in our relationships with our development,
  manufacturing and marketing partners;

- - the impact of future investments, acquisitions and dispositions, and
  any delays, unexpected costs or other problems experienced in
  connection with such transactions, including any liabilities
  associated with the sale of our minority interest in Aventis
  CropScience;

- - changes in environmental laws and regulations, which could cause us
  to incur significant costs in connection with ongoing compliance or
  liability for remediation; and

- - other risks, uncertainties and factors inherent in our business.

These and other risks, uncertainties and factors are discussed in the
Company's Form 20-F Annual Report and other filings with the Securities and
Exchange Commission, including this Form 6-K. Shareholders and prospective
investors are cautioned not to place undue reliance on these forward-
looking statements which speak only as to the Company's judgment as of the
date hereof. Any such forward-looking statements are not intended to give
any assurance as to future results. The Company undertakes no obligation to
publicly update or revise any of these forward-looking statements, whether
to reflect new information or future events or circumstances or otherwise.